nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenylpropanolamine—ADRA2A—epilepsy syndrome	0.202	1	CbGaD
Phenylpropanolamine—MAOA—Zonisamide—epilepsy syndrome	0.0699	0.455	CbGbCtD
Phenylpropanolamine—L-Phenylalanine—Felbamate—epilepsy syndrome	0.0671	0.175	CrCrCtD
Phenylpropanolamine—Phenelzine—Lacosamide—epilepsy syndrome	0.0644	0.168	CrCrCtD
Phenylpropanolamine—Phentermine—Lacosamide—epilepsy syndrome	0.062	0.162	CrCrCtD
Phenylpropanolamine—Dextroamphetamine—Lacosamide—epilepsy syndrome	0.0507	0.132	CrCrCtD
Phenylpropanolamine—Amphetamine—Lacosamide—epilepsy syndrome	0.0507	0.132	CrCrCtD
Phenylpropanolamine—Methamphetamine—Lacosamide—epilepsy syndrome	0.0492	0.129	CrCrCtD
Phenylpropanolamine—L-Phenylalanine—Lacosamide—epilepsy syndrome	0.0386	0.101	CrCrCtD
Phenylpropanolamine—CYP1A2—Carbamazepine—epilepsy syndrome	0.017	0.111	CbGbCtD
Phenylpropanolamine—CYP1A2—Primidone—epilepsy syndrome	0.0159	0.103	CbGbCtD
Phenylpropanolamine—CYP1A2—Propofol—epilepsy syndrome	0.0142	0.0926	CbGbCtD
Phenylpropanolamine—CYP1A2—Phenobarbital—epilepsy syndrome	0.0136	0.0885	CbGbCtD
Phenylpropanolamine—CYP1A2—Diazepam—epilepsy syndrome	0.0129	0.0839	CbGbCtD
Phenylpropanolamine—CYP1A2—Valproic Acid—epilepsy syndrome	0.0102	0.0662	CbGbCtD
Phenylpropanolamine—SLC6A2—locus ceruleus—epilepsy syndrome	0.00376	0.0882	CbGeAlD
Phenylpropanolamine—MAOA—locus ceruleus—epilepsy syndrome	0.00347	0.0813	CbGeAlD
Phenylpropanolamine—DRD1—telencephalic ventricle—epilepsy syndrome	0.00275	0.0645	CbGeAlD
Phenylpropanolamine—SLC6A3—telencephalic ventricle—epilepsy syndrome	0.00221	0.0518	CbGeAlD
Phenylpropanolamine—SLC6A2—autonomic nervous system—epilepsy syndrome	0.002	0.0469	CbGeAlD
Phenylpropanolamine—DRD1—ganglion—epilepsy syndrome	0.00171	0.0402	CbGeAlD
Phenylpropanolamine—SLC6A3—ganglion—epilepsy syndrome	0.00138	0.0323	CbGeAlD
Phenylpropanolamine—SLC6A2—ganglion—epilepsy syndrome	0.00111	0.026	CbGeAlD
Phenylpropanolamine—SLC6A3—hindbrain—epilepsy syndrome	0.00104	0.0245	CbGeAlD
Phenylpropanolamine—MAOA—ganglion—epilepsy syndrome	0.00102	0.024	CbGeAlD
Phenylpropanolamine—ADRA1A—hindbrain—epilepsy syndrome	0.000783	0.0184	CbGeAlD
Phenylpropanolamine—MAOA—hindbrain—epilepsy syndrome	0.000776	0.0182	CbGeAlD
Phenylpropanolamine—DRD1—brainstem—epilepsy syndrome	0.000744	0.0175	CbGeAlD
Phenylpropanolamine—DRD1—forebrain—epilepsy syndrome	0.000718	0.0168	CbGeAlD
Phenylpropanolamine—DRD1—telencephalon—epilepsy syndrome	0.000661	0.0155	CbGeAlD
Phenylpropanolamine—SLC6A3—brainstem—epilepsy syndrome	0.000598	0.014	CbGeAlD
Phenylpropanolamine—SLC6A3—forebrain—epilepsy syndrome	0.000577	0.0135	CbGeAlD
Phenylpropanolamine—ADRB1—forebrain—epilepsy syndrome	0.000548	0.0128	CbGeAlD
Phenylpropanolamine—SLC6A3—telencephalon—epilepsy syndrome	0.000531	0.0124	CbGeAlD
Phenylpropanolamine—ADRB1—telencephalon—epilepsy syndrome	0.000504	0.0118	CbGeAlD
Phenylpropanolamine—SLC6A2—brainstem—epilepsy syndrome	0.000483	0.0113	CbGeAlD
Phenylpropanolamine—DRD1—midbrain—epilepsy syndrome	0.000474	0.0111	CbGeAlD
Phenylpropanolamine—SLC6A2—forebrain—epilepsy syndrome	0.000466	0.0109	CbGeAlD
Phenylpropanolamine—ADRA1A—brainstem—epilepsy syndrome	0.000449	0.0105	CbGeAlD
Phenylpropanolamine—MAOA—brainstem—epilepsy syndrome	0.000445	0.0104	CbGeAlD
Phenylpropanolamine—ADRA1A—forebrain—epilepsy syndrome	0.000433	0.0102	CbGeAlD
Phenylpropanolamine—MAOA—forebrain—epilepsy syndrome	0.000429	0.0101	CbGeAlD
Phenylpropanolamine—SLC6A2—telencephalon—epilepsy syndrome	0.000428	0.01	CbGeAlD
Phenylpropanolamine—Phenelzine—ABAT—epilepsy syndrome	0.000427	0.163	CrCbGaD
Phenylpropanolamine—DRD1—head—epilepsy syndrome	0.000411	0.00965	CbGeAlD
Phenylpropanolamine—ADRA1A—telencephalon—epilepsy syndrome	0.000398	0.00934	CbGeAlD
Phenylpropanolamine—MAOA—telencephalon—epilepsy syndrome	0.000395	0.00925	CbGeAlD
Phenylpropanolamine—DRD1—nervous system—epilepsy syndrome	0.00039	0.00915	CbGeAlD
Phenylpropanolamine—SLC6A3—midbrain—epilepsy syndrome	0.000381	0.00894	CbGeAlD
Phenylpropanolamine—DRD1—central nervous system—epilepsy syndrome	0.000376	0.00881	CbGeAlD
Phenylpropanolamine—SLC6A3—spinal cord—epilepsy syndrome	0.000372	0.00872	CbGeAlD
Phenylpropanolamine—SLC6A2—medulla oblongata—epilepsy syndrome	0.000337	0.00789	CbGeAlD
Phenylpropanolamine—SLC6A3—head—epilepsy syndrome	0.000331	0.00775	CbGeAlD
Phenylpropanolamine—ADRA2A—forebrain—epilepsy syndrome	0.000329	0.00772	CbGeAlD
Phenylpropanolamine—L-Phenylalanine—TH—epilepsy syndrome	0.000322	0.123	CrCbGaD
Phenylpropanolamine—ADRB1—head—epilepsy syndrome	0.000314	0.00735	CbGeAlD
Phenylpropanolamine—SLC6A3—nervous system—epilepsy syndrome	0.000313	0.00735	CbGeAlD
Phenylpropanolamine—MAOA—medulla oblongata—epilepsy syndrome	0.00031	0.00727	CbGeAlD
Phenylpropanolamine—ADRA2A—telencephalon—epilepsy syndrome	0.000303	0.0071	CbGeAlD
Phenylpropanolamine—SLC6A3—central nervous system—epilepsy syndrome	0.000302	0.00708	CbGeAlD
Phenylpropanolamine—DRD1—brain—epilepsy syndrome	0.000298	0.00699	CbGeAlD
Phenylpropanolamine—ADRB1—nervous system—epilepsy syndrome	0.000297	0.00697	CbGeAlD
Phenylpropanolamine—SLC6A3—cerebellum—epilepsy syndrome	0.000295	0.00692	CbGeAlD
Phenylpropanolamine—ADRB1—central nervous system—epilepsy syndrome	0.000286	0.00671	CbGeAlD
Phenylpropanolamine—MAOA—midbrain—epilepsy syndrome	0.000283	0.00665	CbGeAlD
Phenylpropanolamine—MAOA—spinal cord—epilepsy syndrome	0.000277	0.00648	CbGeAlD
Phenylpropanolamine—SLC6A2—head—epilepsy syndrome	0.000267	0.00625	CbGeAlD
Phenylpropanolamine—SLC6A2—nervous system—epilepsy syndrome	0.000253	0.00593	CbGeAlD
Phenylpropanolamine—ADRA1A—head—epilepsy syndrome	0.000248	0.00581	CbGeAlD
Phenylpropanolamine—MAOA—head—epilepsy syndrome	0.000246	0.00576	CbGeAlD
Phenylpropanolamine—SLC6A2—central nervous system—epilepsy syndrome	0.000243	0.00571	CbGeAlD
Phenylpropanolamine—SLC6A3—brain—epilepsy syndrome	0.00024	0.00562	CbGeAlD
Phenylpropanolamine—ADRA2A—medulla oblongata—epilepsy syndrome	0.000238	0.00558	CbGeAlD
Phenylpropanolamine—ADRA1A—nervous system—epilepsy syndrome	0.000235	0.00551	CbGeAlD
Phenylpropanolamine—MAOA—nervous system—epilepsy syndrome	0.000233	0.00546	CbGeAlD
Phenylpropanolamine—ADRB1—brain—epilepsy syndrome	0.000227	0.00533	CbGeAlD
Phenylpropanolamine—ADRA1A—central nervous system—epilepsy syndrome	0.000226	0.00531	CbGeAlD
Phenylpropanolamine—MAOA—central nervous system—epilepsy syndrome	0.000224	0.00526	CbGeAlD
Phenylpropanolamine—ADRA1A—cerebellum—epilepsy syndrome	0.000221	0.00519	CbGeAlD
Phenylpropanolamine—MAOA—cerebellum—epilepsy syndrome	0.000219	0.00514	CbGeAlD
Phenylpropanolamine—ADRA2A—midbrain—epilepsy syndrome	0.000217	0.0051	CbGeAlD
Phenylpropanolamine—Levonordefrin—ADRA2A—epilepsy syndrome	0.000213	0.0814	CrCbGaD
Phenylpropanolamine—ADRA2A—spinal cord—epilepsy syndrome	0.000212	0.00497	CbGeAlD
Phenylpropanolamine—SLC6A2—brain—epilepsy syndrome	0.000193	0.00453	CbGeAlD
Phenylpropanolamine—ADRA2A—head—epilepsy syndrome	0.000189	0.00442	CbGeAlD
Phenylpropanolamine—ADRA1A—brain—epilepsy syndrome	0.00018	0.00421	CbGeAlD
Phenylpropanolamine—ADRA2A—nervous system—epilepsy syndrome	0.000179	0.00419	CbGeAlD
Phenylpropanolamine—MAOA—brain—epilepsy syndrome	0.000178	0.00418	CbGeAlD
Phenylpropanolamine—Ephedrine—BCHE—epilepsy syndrome	0.000178	0.068	CrCbGaD
Phenylpropanolamine—ADRA2A—central nervous system—epilepsy syndrome	0.000172	0.00404	CbGeAlD
Phenylpropanolamine—ADRA2A—cerebellum—epilepsy syndrome	0.000168	0.00394	CbGeAlD
Phenylpropanolamine—Constipation—Levetiracetam—epilepsy syndrome	0.000149	0.00113	CcSEcCtD
Phenylpropanolamine—Psychotic disorder—Topiramate—epilepsy syndrome	0.000149	0.00113	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Propofol—epilepsy syndrome	0.000149	0.00113	CcSEcCtD
Phenylpropanolamine—Confusional state—Clonazepam—epilepsy syndrome	0.000149	0.00113	CcSEcCtD
Phenylpropanolamine—Dizziness—Lacosamide—epilepsy syndrome	0.000149	0.00112	CcSEcCtD
Phenylpropanolamine—Insomnia—Vigabatrin—epilepsy syndrome	0.000148	0.00112	CcSEcCtD
Phenylpropanolamine—Confusional state—Phenytoin—epilepsy syndrome	0.000148	0.00112	CcSEcCtD
Phenylpropanolamine—Confusional state—Oxcarbazepine—epilepsy syndrome	0.000147	0.00111	CcSEcCtD
Phenylpropanolamine—Insomnia—Diazepam—epilepsy syndrome	0.000146	0.00111	CcSEcCtD
Phenylpropanolamine—Hypotension—Felbamate—epilepsy syndrome	0.000146	0.00111	CcSEcCtD
Phenylpropanolamine—Somnolence—Vigabatrin—epilepsy syndrome	0.000146	0.0011	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Midazolam—epilepsy syndrome	0.000146	0.0011	CcSEcCtD
Phenylpropanolamine—Irritability—Topiramate—epilepsy syndrome	0.000146	0.0011	CcSEcCtD
Phenylpropanolamine—Anxiety—Carbamazepine—epilepsy syndrome	0.000145	0.0011	CcSEcCtD
Phenylpropanolamine—Urinary retention—Topiramate—epilepsy syndrome	0.000145	0.0011	CcSEcCtD
Phenylpropanolamine—Nausea—Phenobarbital—epilepsy syndrome	0.000145	0.0011	CcSEcCtD
Phenylpropanolamine—Dizziness—Clobazam—epilepsy syndrome	0.000144	0.00109	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Diazepam—epilepsy syndrome	0.000144	0.00109	CcSEcCtD
Phenylpropanolamine—Tachycardia—Clonazepam—epilepsy syndrome	0.000144	0.00109	CcSEcCtD
Phenylpropanolamine—Constipation—Fosphenytoin—epilepsy syndrome	0.000144	0.00109	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Levetiracetam—epilepsy syndrome	0.000144	0.00109	CcSEcCtD
Phenylpropanolamine—Somnolence—Diazepam—epilepsy syndrome	0.000144	0.00109	CcSEcCtD
Phenylpropanolamine—Ataxia—Topiramate—epilepsy syndrome	0.000143	0.00108	CcSEcCtD
Phenylpropanolamine—Hypotension—Zonisamide—epilepsy syndrome	0.000143	0.00108	CcSEcCtD
Phenylpropanolamine—Tachycardia—Phenytoin—epilepsy syndrome	0.000143	0.00108	CcSEcCtD
Phenylpropanolamine—Vomiting—Lacosamide—epilepsy syndrome	0.000143	0.00108	CcSEcCtD
Phenylpropanolamine—Tachycardia—Oxcarbazepine—epilepsy syndrome	0.000142	0.00108	CcSEcCtD
Phenylpropanolamine—Nausea—Rufinamide—epilepsy syndrome	0.000142	0.00108	CcSEcCtD
Phenylpropanolamine—Rash—Lacosamide—epilepsy syndrome	0.000142	0.00107	CcSEcCtD
Phenylpropanolamine—Dermatitis—Lacosamide—epilepsy syndrome	0.000142	0.00107	CcSEcCtD
Phenylpropanolamine—Insomnia—Felbamate—epilepsy syndrome	0.000141	0.00107	CcSEcCtD
Phenylpropanolamine—Confusional state—Carbamazepine—epilepsy syndrome	0.000141	0.00107	CcSEcCtD
Phenylpropanolamine—Anxiety—Lamotrigine—epilepsy syndrome	0.000141	0.00106	CcSEcCtD
Phenylpropanolamine—Constipation—Vigabatrin—epilepsy syndrome	0.00014	0.00106	CcSEcCtD
Phenylpropanolamine—Drowsiness—Gabapentin—epilepsy syndrome	0.00014	0.00106	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Felbamate—epilepsy syndrome	0.000139	0.00105	CcSEcCtD
Phenylpropanolamine—Somnolence—Felbamate—epilepsy syndrome	0.000139	0.00105	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Fosphenytoin—epilepsy syndrome	0.000139	0.00105	CcSEcCtD
Phenylpropanolamine—Vomiting—Clobazam—epilepsy syndrome	0.000139	0.00105	CcSEcCtD
Phenylpropanolamine—Insomnia—Zonisamide—epilepsy syndrome	0.000138	0.00105	CcSEcCtD
Phenylpropanolamine—Constipation—Diazepam—epilepsy syndrome	0.000138	0.00105	CcSEcCtD
Phenylpropanolamine—Hypotension—Clonazepam—epilepsy syndrome	0.000138	0.00104	CcSEcCtD
Phenylpropanolamine—Pseudoephedrine—ADRA2A—epilepsy syndrome	0.000138	0.0527	CrCbGaD
Phenylpropanolamine—Rash—Clobazam—epilepsy syndrome	0.000138	0.00104	CcSEcCtD
Phenylpropanolamine—Dermatitis—Clobazam—epilepsy syndrome	0.000137	0.00104	CcSEcCtD
Phenylpropanolamine—Hypotension—Phenytoin—epilepsy syndrome	0.000137	0.00104	CcSEcCtD
Phenylpropanolamine—ADRA2A—brain—epilepsy syndrome	0.000137	0.0032	CbGeAlD
Phenylpropanolamine—Tachycardia—Carbamazepine—epilepsy syndrome	0.000137	0.00103	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Zonisamide—epilepsy syndrome	0.000137	0.00103	CcSEcCtD
Phenylpropanolamine—Confusional state—Lamotrigine—epilepsy syndrome	0.000136	0.00103	CcSEcCtD
Phenylpropanolamine—Hypotension—Oxcarbazepine—epilepsy syndrome	0.000136	0.00103	CcSEcCtD
Phenylpropanolamine—Somnolence—Zonisamide—epilepsy syndrome	0.000136	0.00103	CcSEcCtD
Phenylpropanolamine—Hallucination—Pregabalin—epilepsy syndrome	0.000136	0.00103	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Vigabatrin—epilepsy syndrome	0.000135	0.00102	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Valproic Acid—epilepsy syndrome	0.000135	0.00102	CcSEcCtD
Phenylpropanolamine—Constipation—Felbamate—epilepsy syndrome	0.000134	0.00101	CcSEcCtD
Phenylpropanolamine—Nausea—Lacosamide—epilepsy syndrome	0.000134	0.00101	CcSEcCtD
Phenylpropanolamine—Insomnia—Clonazepam—epilepsy syndrome	0.000133	0.00101	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Diazepam—epilepsy syndrome	0.000133	0.00101	CcSEcCtD
Phenylpropanolamine—Insomnia—Phenytoin—epilepsy syndrome	0.000133	0.001	CcSEcCtD
Phenylpropanolamine—Tachycardia—Lamotrigine—epilepsy syndrome	0.000132	0.000998	CcSEcCtD
Phenylpropanolamine—Insomnia—Oxcarbazepine—epilepsy syndrome	0.000132	0.000997	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Clonazepam—epilepsy syndrome	0.000132	0.000995	CcSEcCtD
Phenylpropanolamine—Somnolence—Clonazepam—epilepsy syndrome	0.000131	0.000992	CcSEcCtD
Phenylpropanolamine—Constipation—Zonisamide—epilepsy syndrome	0.000131	0.00099	CcSEcCtD
Phenylpropanolamine—Hypotension—Carbamazepine—epilepsy syndrome	0.000131	0.000989	CcSEcCtD
Phenylpropanolamine—Pseudoephedrine—TNF—epilepsy syndrome	0.000131	0.05	CrCbGaD
Phenylpropanolamine—Dyspnoea—Phenytoin—epilepsy syndrome	0.000131	0.000988	CcSEcCtD
Phenylpropanolamine—Somnolence—Phenytoin—epilepsy syndrome	0.00013	0.000985	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Midazolam—epilepsy syndrome	0.00013	0.000984	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Oxcarbazepine—epilepsy syndrome	0.00013	0.000983	CcSEcCtD
Phenylpropanolamine—Somnolence—Oxcarbazepine—epilepsy syndrome	0.00013	0.00098	CcSEcCtD
Phenylpropanolamine—Nausea—Clobazam—epilepsy syndrome	0.00013	0.00098	CcSEcCtD
Phenylpropanolamine—Tension—Valproic Acid—epilepsy syndrome	0.000129	0.000977	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Felbamate—epilepsy syndrome	0.000129	0.000975	CcSEcCtD
Phenylpropanolamine—Dizziness—Acetazolamide—epilepsy syndrome	0.000129	0.000972	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Levetiracetam—epilepsy syndrome	0.000129	0.000972	CcSEcCtD
Phenylpropanolamine—Nervousness—Valproic Acid—epilepsy syndrome	0.000128	0.000967	CcSEcCtD
Phenylpropanolamine—Flushing—Pregabalin—epilepsy syndrome	0.000127	0.00096	CcSEcCtD
Phenylpropanolamine—Insomnia—Carbamazepine—epilepsy syndrome	0.000127	0.000957	CcSEcCtD
Phenylpropanolamine—Constipation—Clonazepam—epilepsy syndrome	0.000126	0.000954	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Zonisamide—epilepsy syndrome	0.000126	0.000954	CcSEcCtD
Phenylpropanolamine—Tranylcypromine—CYP2C19—epilepsy syndrome	0.000126	0.048	CrCbGaD
Phenylpropanolamine—Constipation—Phenytoin—epilepsy syndrome	0.000125	0.000948	CcSEcCtD
Phenylpropanolamine—Hallucination—Gabapentin—epilepsy syndrome	0.000125	0.000943	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Carbamazepine—epilepsy syndrome	0.000125	0.000943	CcSEcCtD
Phenylpropanolamine—Constipation—Oxcarbazepine—epilepsy syndrome	0.000125	0.000943	CcSEcCtD
Phenylpropanolamine—Somnolence—Carbamazepine—epilepsy syndrome	0.000124	0.000941	CcSEcCtD
Phenylpropanolamine—Vision blurred—Valproic Acid—epilepsy syndrome	0.000124	0.000938	CcSEcCtD
Phenylpropanolamine—Vomiting—Acetazolamide—epilepsy syndrome	0.000124	0.000935	CcSEcCtD
Phenylpropanolamine—Tremor—Valproic Acid—epilepsy syndrome	0.000123	0.000933	CcSEcCtD
Phenylpropanolamine—Insomnia—Lamotrigine—epilepsy syndrome	0.000122	0.000925	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Pregabalin—epilepsy syndrome	0.000122	0.000924	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Clonazepam—epilepsy syndrome	0.000122	0.00092	CcSEcCtD
Phenylpropanolamine—Agitation—Valproic Acid—epilepsy syndrome	0.000121	0.000915	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Vigabatrin—epilepsy syndrome	0.000121	0.000915	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Phenytoin—epilepsy syndrome	0.000121	0.000913	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Lamotrigine—epilepsy syndrome	0.000121	0.000912	CcSEcCtD
Phenylpropanolamine—Somnolence—Lamotrigine—epilepsy syndrome	0.00012	0.000909	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Oxcarbazepine—epilepsy syndrome	0.00012	0.000909	CcSEcCtD
Phenylpropanolamine—Constipation—Carbamazepine—epilepsy syndrome	0.00012	0.000905	CcSEcCtD
Phenylpropanolamine—Dizziness—Propofol—epilepsy syndrome	0.000119	0.000903	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Diazepam—epilepsy syndrome	0.000119	0.0009	CcSEcCtD
Phenylpropanolamine—Dizziness—Midazolam—epilepsy syndrome	0.000117	0.000884	CcSEcCtD
Phenylpropanolamine—Tension—Pregabalin—epilepsy syndrome	0.000117	0.000883	CcSEcCtD
Phenylpropanolamine—Constipation—Lamotrigine—epilepsy syndrome	0.000116	0.000874	CcSEcCtD
Phenylpropanolamine—Nervousness—Pregabalin—epilepsy syndrome	0.000116	0.000874	CcSEcCtD
Phenylpropanolamine—Nausea—Acetazolamide—epilepsy syndrome	0.000116	0.000873	CcSEcCtD
Phenylpropanolamine—Dizziness—Levetiracetam—epilepsy syndrome	0.000115	0.000873	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Carbamazepine—epilepsy syndrome	0.000115	0.000872	CcSEcCtD
Phenylpropanolamine—Vomiting—Propofol—epilepsy syndrome	0.000115	0.000868	CcSEcCtD
Phenylpropanolamine—Rash—Propofol—epilepsy syndrome	0.000114	0.000861	CcSEcCtD
Phenylpropanolamine—Dermatitis—Propofol—epilepsy syndrome	0.000114	0.00086	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Zonisamide—epilepsy syndrome	0.000113	0.000853	CcSEcCtD
Phenylpropanolamine—Vomiting—Midazolam—epilepsy syndrome	0.000112	0.00085	CcSEcCtD
Phenylpropanolamine—Vision blurred—Pregabalin—epilepsy syndrome	0.000112	0.000848	CcSEcCtD
Phenylpropanolamine—Anxiety—Valproic Acid—epilepsy syndrome	0.000112	0.000845	CcSEcCtD
Phenylpropanolamine—Tremor—Pregabalin—epilepsy syndrome	0.000112	0.000843	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Lamotrigine—epilepsy syndrome	0.000111	0.000843	CcSEcCtD
Phenylpropanolamine—Rash—Midazolam—epilepsy syndrome	0.000111	0.000842	CcSEcCtD
Phenylpropanolamine—Dizziness—Fosphenytoin—epilepsy syndrome	0.000111	0.000842	CcSEcCtD
Phenylpropanolamine—Dermatitis—Midazolam—epilepsy syndrome	0.000111	0.000842	CcSEcCtD
Phenylpropanolamine—Vomiting—Levetiracetam—epilepsy syndrome	0.000111	0.000839	CcSEcCtD
Phenylpropanolamine—Phentermine—SLC6A4—epilepsy syndrome	0.000111	0.0424	CrCbGaD
Phenylpropanolamine—Rash—Levetiracetam—epilepsy syndrome	0.00011	0.000832	CcSEcCtD
Phenylpropanolamine—Dermatitis—Levetiracetam—epilepsy syndrome	0.00011	0.000831	CcSEcCtD
Phenylpropanolamine—Agitation—Pregabalin—epilepsy syndrome	0.000109	0.000827	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Clonazepam—epilepsy syndrome	0.000109	0.000822	CcSEcCtD
Phenylpropanolamine—Dizziness—Vigabatrin—epilepsy syndrome	0.000109	0.000821	CcSEcCtD
Phenylpropanolamine—Confusional state—Valproic Acid—epilepsy syndrome	0.000108	0.000819	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Phenytoin—epilepsy syndrome	0.000108	0.000817	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Oxcarbazepine—epilepsy syndrome	0.000107	0.000812	CcSEcCtD
Phenylpropanolamine—Nausea—Propofol—epilepsy syndrome	0.000107	0.000811	CcSEcCtD
Phenylpropanolamine—Tension—Gabapentin—epilepsy syndrome	0.000107	0.00081	CcSEcCtD
Phenylpropanolamine—Vomiting—Fosphenytoin—epilepsy syndrome	0.000107	0.00081	CcSEcCtD
Phenylpropanolamine—Dizziness—Diazepam—epilepsy syndrome	0.000107	0.000808	CcSEcCtD
Phenylpropanolamine—Rash—Fosphenytoin—epilepsy syndrome	0.000106	0.000803	CcSEcCtD
Phenylpropanolamine—Dermatitis—Fosphenytoin—epilepsy syndrome	0.000106	0.000802	CcSEcCtD
Phenylpropanolamine—Nervousness—Gabapentin—epilepsy syndrome	0.000106	0.000802	CcSEcCtD
Phenylpropanolamine—Pseudoephedrine—SLC6A4—epilepsy syndrome	0.000105	0.0402	CrCbGaD
Phenylpropanolamine—Nausea—Midazolam—epilepsy syndrome	0.000105	0.000794	CcSEcCtD
Phenylpropanolamine—Hallucination—Topiramate—epilepsy syndrome	0.000105	0.000794	CcSEcCtD
Phenylpropanolamine—Tachycardia—Valproic Acid—epilepsy syndrome	0.000105	0.000793	CcSEcCtD
Phenylpropanolamine—Vomiting—Vigabatrin—epilepsy syndrome	0.000104	0.000789	CcSEcCtD
Phenylpropanolamine—Nausea—Levetiracetam—epilepsy syndrome	0.000104	0.000784	CcSEcCtD
Phenylpropanolamine—Methamphetamine—ADRA2A—epilepsy syndrome	0.000104	0.0396	CrCbGaD
Phenylpropanolamine—Rash—Vigabatrin—epilepsy syndrome	0.000104	0.000783	CcSEcCtD
Phenylpropanolamine—Dizziness—Felbamate—epilepsy syndrome	0.000103	0.000782	CcSEcCtD
Phenylpropanolamine—Dermatitis—Vigabatrin—epilepsy syndrome	0.000103	0.000782	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Carbamazepine—epilepsy syndrome	0.000103	0.000779	CcSEcCtD
Phenylpropanolamine—Vision blurred—Gabapentin—epilepsy syndrome	0.000103	0.000778	CcSEcCtD
Phenylpropanolamine—Vomiting—Diazepam—epilepsy syndrome	0.000103	0.000777	CcSEcCtD
Phenylpropanolamine—Tremor—Gabapentin—epilepsy syndrome	0.000102	0.000773	CcSEcCtD
Phenylpropanolamine—Rash—Diazepam—epilepsy syndrome	0.000102	0.000771	CcSEcCtD
Phenylpropanolamine—Dermatitis—Diazepam—epilepsy syndrome	0.000102	0.00077	CcSEcCtD
Phenylpropanolamine—Dizziness—Zonisamide—epilepsy syndrome	0.000101	0.000766	CcSEcCtD
Phenylpropanolamine—Anxiety—Pregabalin—epilepsy syndrome	0.000101	0.000764	CcSEcCtD
Phenylpropanolamine—Hypotension—Valproic Acid—epilepsy syndrome	0.0001	0.000759	CcSEcCtD
Phenylpropanolamine—Agitation—Gabapentin—epilepsy syndrome	0.0001	0.000758	CcSEcCtD
Phenylpropanolamine—Nausea—Fosphenytoin—epilepsy syndrome	0.0001	0.000756	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Lamotrigine—epilepsy syndrome	9.96e-05	0.000753	CcSEcCtD
Phenylpropanolamine—Vomiting—Felbamate—epilepsy syndrome	9.95e-05	0.000752	CcSEcCtD
Phenylpropanolamine—Rash—Felbamate—epilepsy syndrome	9.86e-05	0.000746	CcSEcCtD
Phenylpropanolamine—Dermatitis—Felbamate—epilepsy syndrome	9.85e-05	0.000745	CcSEcCtD
Phenylpropanolamine—Confusional state—Pregabalin—epilepsy syndrome	9.8e-05	0.000741	CcSEcCtD
Phenylpropanolamine—Flushing—Topiramate—epilepsy syndrome	9.79e-05	0.00074	CcSEcCtD
Phenylpropanolamine—Dizziness—Clonazepam—epilepsy syndrome	9.76e-05	0.000738	CcSEcCtD
Phenylpropanolamine—Nausea—Vigabatrin—epilepsy syndrome	9.75e-05	0.000737	CcSEcCtD
Phenylpropanolamine—Vomiting—Zonisamide—epilepsy syndrome	9.74e-05	0.000736	CcSEcCtD
Phenylpropanolamine—Insomnia—Valproic Acid—epilepsy syndrome	9.72e-05	0.000735	CcSEcCtD
Phenylpropanolamine—Dizziness—Phenytoin—epilepsy syndrome	9.69e-05	0.000733	CcSEcCtD
Phenylpropanolamine—Rash—Zonisamide—epilepsy syndrome	9.65e-05	0.00073	CcSEcCtD
Phenylpropanolamine—Dermatitis—Zonisamide—epilepsy syndrome	9.65e-05	0.000729	CcSEcCtD
Phenylpropanolamine—Dizziness—Oxcarbazepine—epilepsy syndrome	9.64e-05	0.000729	CcSEcCtD
Phenylpropanolamine—Nausea—Diazepam—epilepsy syndrome	9.6e-05	0.000726	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Valproic Acid—epilepsy syndrome	9.58e-05	0.000724	CcSEcCtD
Phenylpropanolamine—Somnolence—Valproic Acid—epilepsy syndrome	9.55e-05	0.000722	CcSEcCtD
Phenylpropanolamine—Tachycardia—Pregabalin—epilepsy syndrome	9.48e-05	0.000717	CcSEcCtD
Phenylpropanolamine—Vomiting—Clonazepam—epilepsy syndrome	9.38e-05	0.000709	CcSEcCtD
Phenylpropanolamine—Vomiting—Phenytoin—epilepsy syndrome	9.32e-05	0.000705	CcSEcCtD
Phenylpropanolamine—Tranylcypromine—CYP2D6—epilepsy syndrome	9.31e-05	0.0356	CrCbGaD
Phenylpropanolamine—Rash—Clonazepam—epilepsy syndrome	9.3e-05	0.000704	CcSEcCtD
Phenylpropanolamine—Dermatitis—Clonazepam—epilepsy syndrome	9.3e-05	0.000703	CcSEcCtD
Phenylpropanolamine—Nausea—Felbamate—epilepsy syndrome	9.29e-05	0.000703	CcSEcCtD
Phenylpropanolamine—Vomiting—Oxcarbazepine—epilepsy syndrome	9.27e-05	0.000701	CcSEcCtD
Phenylpropanolamine—Anxiety—Gabapentin—epilepsy syndrome	9.26e-05	0.0007	CcSEcCtD
Phenylpropanolamine—Dizziness—Carbamazepine—epilepsy syndrome	9.25e-05	0.0007	CcSEcCtD
Phenylpropanolamine—Rash—Phenytoin—epilepsy syndrome	9.24e-05	0.000699	CcSEcCtD
Phenylpropanolamine—Dermatitis—Phenytoin—epilepsy syndrome	9.23e-05	0.000698	CcSEcCtD
Phenylpropanolamine—Rash—Oxcarbazepine—epilepsy syndrome	9.19e-05	0.000695	CcSEcCtD
Phenylpropanolamine—Constipation—Valproic Acid—epilepsy syndrome	9.19e-05	0.000695	CcSEcCtD
Phenylpropanolamine—Dermatitis—Oxcarbazepine—epilepsy syndrome	9.18e-05	0.000694	CcSEcCtD
Phenylpropanolamine—Nausea—Zonisamide—epilepsy syndrome	9.09e-05	0.000688	CcSEcCtD
Phenylpropanolamine—Hypotension—Pregabalin—epilepsy syndrome	9.08e-05	0.000686	CcSEcCtD
Phenylpropanolamine—Tension—Topiramate—epilepsy syndrome	9.01e-05	0.000681	CcSEcCtD
Phenylpropanolamine—Confusional state—Gabapentin—epilepsy syndrome	8.98e-05	0.000679	CcSEcCtD
Phenylpropanolamine—Dizziness—Lamotrigine—epilepsy syndrome	8.94e-05	0.000676	CcSEcCtD
Phenylpropanolamine—Nervousness—Topiramate—epilepsy syndrome	8.92e-05	0.000674	CcSEcCtD
Phenylpropanolamine—Vomiting—Carbamazepine—epilepsy syndrome	8.9e-05	0.000673	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Valproic Acid—epilepsy syndrome	8.85e-05	0.00067	CcSEcCtD
Phenylpropanolamine—Rash—Carbamazepine—epilepsy syndrome	8.82e-05	0.000667	CcSEcCtD
Phenylpropanolamine—Dermatitis—Carbamazepine—epilepsy syndrome	8.81e-05	0.000666	CcSEcCtD
Phenylpropanolamine—Insomnia—Pregabalin—epilepsy syndrome	8.79e-05	0.000664	CcSEcCtD
Phenylpropanolamine—Nausea—Clonazepam—epilepsy syndrome	8.77e-05	0.000663	CcSEcCtD
Phenylpropanolamine—Nausea—Phenytoin—epilepsy syndrome	8.71e-05	0.000658	CcSEcCtD
Phenylpropanolamine—Tachycardia—Gabapentin—epilepsy syndrome	8.69e-05	0.000657	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Pregabalin—epilepsy syndrome	8.66e-05	0.000655	CcSEcCtD
Phenylpropanolamine—Nausea—Oxcarbazepine—epilepsy syndrome	8.66e-05	0.000655	CcSEcCtD
Phenylpropanolamine—Vision blurred—Topiramate—epilepsy syndrome	8.65e-05	0.000654	CcSEcCtD
Phenylpropanolamine—Somnolence—Pregabalin—epilepsy syndrome	8.64e-05	0.000653	CcSEcCtD
Phenylpropanolamine—Tremor—Topiramate—epilepsy syndrome	8.6e-05	0.000651	CcSEcCtD
Phenylpropanolamine—Vomiting—Lamotrigine—epilepsy syndrome	8.6e-05	0.00065	CcSEcCtD
Phenylpropanolamine—Phenelzine—CYP2C19—epilepsy syndrome	8.57e-05	0.0328	CrCbGaD
Phenylpropanolamine—Amphetamine—SLC6A4—epilepsy syndrome	8.53e-05	0.0326	CrCbGaD
Phenylpropanolamine—Rash—Lamotrigine—epilepsy syndrome	8.53e-05	0.000645	CcSEcCtD
Phenylpropanolamine—Dermatitis—Lamotrigine—epilepsy syndrome	8.52e-05	0.000644	CcSEcCtD
Phenylpropanolamine—Agitation—Topiramate—epilepsy syndrome	8.44e-05	0.000638	CcSEcCtD
Phenylpropanolamine—Hypotension—Gabapentin—epilepsy syndrome	8.32e-05	0.000629	CcSEcCtD
Phenylpropanolamine—Nausea—Carbamazepine—epilepsy syndrome	8.31e-05	0.000628	CcSEcCtD
Phenylpropanolamine—Constipation—Pregabalin—epilepsy syndrome	8.31e-05	0.000628	CcSEcCtD
Phenylpropanolamine—Insomnia—Gabapentin—epilepsy syndrome	8.06e-05	0.000609	CcSEcCtD
Phenylpropanolamine—Nausea—Lamotrigine—epilepsy syndrome	8.03e-05	0.000607	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Pregabalin—epilepsy syndrome	8.01e-05	0.000605	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Gabapentin—epilepsy syndrome	7.94e-05	0.000601	CcSEcCtD
Phenylpropanolamine—Somnolence—Gabapentin—epilepsy syndrome	7.92e-05	0.000599	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Valproic Acid—epilepsy syndrome	7.92e-05	0.000599	CcSEcCtD
Phenylpropanolamine—Methamphetamine—SLC6A4—epilepsy syndrome	7.91e-05	0.0302	CrCbGaD
Phenylpropanolamine—Phentermine—CYP2D6—epilepsy syndrome	7.8e-05	0.0298	CrCbGaD
Phenylpropanolamine—Anxiety—Topiramate—epilepsy syndrome	7.79e-05	0.000589	CcSEcCtD
Phenylpropanolamine—Constipation—Gabapentin—epilepsy syndrome	7.62e-05	0.000576	CcSEcCtD
Phenylpropanolamine—Confusional state—Topiramate—epilepsy syndrome	7.56e-05	0.000571	CcSEcCtD
Phenylpropanolamine—Benzyl alcohol—CYP2D6—epilepsy syndrome	7.52e-05	0.0288	CrCbGaD
Phenylpropanolamine—Dextroamphetamine—CYP2D6—epilepsy syndrome	7.44e-05	0.0285	CrCbGaD
Phenylpropanolamine—Pseudoephedrine—CYP2D6—epilepsy syndrome	7.39e-05	0.0283	CrCbGaD
Phenylpropanolamine—Feeling abnormal—Gabapentin—epilepsy syndrome	7.34e-05	0.000555	CcSEcCtD
Phenylpropanolamine—Tachycardia—Topiramate—epilepsy syndrome	7.31e-05	0.000553	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Pregabalin—epilepsy syndrome	7.16e-05	0.000541	CcSEcCtD
Phenylpropanolamine—Dizziness—Valproic Acid—epilepsy syndrome	7.11e-05	0.000537	CcSEcCtD
Phenylpropanolamine—Hypotension—Topiramate—epilepsy syndrome	7e-05	0.00053	CcSEcCtD
Phenylpropanolamine—Vomiting—Valproic Acid—epilepsy syndrome	6.83e-05	0.000517	CcSEcCtD
Phenylpropanolamine—Insomnia—Topiramate—epilepsy syndrome	6.78e-05	0.000513	CcSEcCtD
Phenylpropanolamine—Rash—Valproic Acid—epilepsy syndrome	6.78e-05	0.000512	CcSEcCtD
Phenylpropanolamine—Dermatitis—Valproic Acid—epilepsy syndrome	6.77e-05	0.000512	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Topiramate—epilepsy syndrome	6.68e-05	0.000505	CcSEcCtD
Phenylpropanolamine—Somnolence—Topiramate—epilepsy syndrome	6.66e-05	0.000504	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Gabapentin—epilepsy syndrome	6.56e-05	0.000496	CcSEcCtD
Phenylpropanolamine—Dizziness—Pregabalin—epilepsy syndrome	6.42e-05	0.000486	CcSEcCtD
Phenylpropanolamine—Constipation—Topiramate—epilepsy syndrome	6.41e-05	0.000485	CcSEcCtD
Phenylpropanolamine—Nausea—Valproic Acid—epilepsy syndrome	6.38e-05	0.000483	CcSEcCtD
Phenylpropanolamine—Vomiting—Pregabalin—epilepsy syndrome	6.18e-05	0.000467	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Topiramate—epilepsy syndrome	6.18e-05	0.000467	CcSEcCtD
Phenylpropanolamine—Rash—Pregabalin—epilepsy syndrome	6.13e-05	0.000463	CcSEcCtD
Phenylpropanolamine—Dermatitis—Pregabalin—epilepsy syndrome	6.12e-05	0.000463	CcSEcCtD
Phenylpropanolamine—Amphetamine—CYP2D6—epilepsy syndrome	6e-05	0.0229	CrCbGaD
Phenylpropanolamine—Dizziness—Gabapentin—epilepsy syndrome	5.89e-05	0.000445	CcSEcCtD
Phenylpropanolamine—Nausea—Pregabalin—epilepsy syndrome	5.77e-05	0.000436	CcSEcCtD
Phenylpropanolamine—Vomiting—Gabapentin—epilepsy syndrome	5.66e-05	0.000428	CcSEcCtD
Phenylpropanolamine—Rash—Gabapentin—epilepsy syndrome	5.62e-05	0.000425	CcSEcCtD
Phenylpropanolamine—Dermatitis—Gabapentin—epilepsy syndrome	5.61e-05	0.000424	CcSEcCtD
Phenylpropanolamine—Methamphetamine—CYP2D6—epilepsy syndrome	5.56e-05	0.0213	CrCbGaD
Phenylpropanolamine—Hypersensitivity—Topiramate—epilepsy syndrome	5.52e-05	0.000418	CcSEcCtD
Phenylpropanolamine—Nausea—Gabapentin—epilepsy syndrome	5.29e-05	0.0004	CcSEcCtD
Phenylpropanolamine—Dizziness—Topiramate—epilepsy syndrome	4.96e-05	0.000375	CcSEcCtD
Phenylpropanolamine—Vomiting—Topiramate—epilepsy syndrome	4.77e-05	0.00036	CcSEcCtD
Phenylpropanolamine—Rash—Topiramate—epilepsy syndrome	4.73e-05	0.000357	CcSEcCtD
Phenylpropanolamine—Dermatitis—Topiramate—epilepsy syndrome	4.72e-05	0.000357	CcSEcCtD
Phenylpropanolamine—Nausea—Topiramate—epilepsy syndrome	4.45e-05	0.000337	CcSEcCtD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CCL3—epilepsy syndrome	4.33e-06	5.14e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PLCB1—epilepsy syndrome	4.3e-06	5.11e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—TH—epilepsy syndrome	4.29e-06	5.09e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—CCR5—epilepsy syndrome	4.27e-06	5.07e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—ADAM10—epilepsy syndrome	4.27e-06	5.06e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—AGT—epilepsy syndrome	4.27e-06	5.06e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—CCL2—epilepsy syndrome	4.25e-06	5.04e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—TXNRD1—epilepsy syndrome	4.25e-06	5.04e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CCR2—epilepsy syndrome	4.21e-06	5e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NTRK2—epilepsy syndrome	4.21e-06	5e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—SST—epilepsy syndrome	4.21e-06	5e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—AGT—epilepsy syndrome	4.19e-06	4.97e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—HTR2A—epilepsy syndrome	4.18e-06	4.96e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—DUSP6—epilepsy syndrome	4.18e-06	4.95e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—HES1—epilepsy syndrome	4.15e-06	4.92e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—S100B—epilepsy syndrome	4.13e-06	4.9e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—ADRA2A—epilepsy syndrome	4.12e-06	4.89e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—AQP1—epilepsy syndrome	4.12e-06	4.89e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—APOE—epilepsy syndrome	4.11e-06	4.87e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PLAT—epilepsy syndrome	4.1e-06	4.87e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—SOCS3—epilepsy syndrome	4.08e-06	4.85e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CDC42—epilepsy syndrome	4.07e-06	4.84e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—S100B—epilepsy syndrome	4.04e-06	4.79e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—FYN—epilepsy syndrome	4.04e-06	4.79e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—PRKCB—epilepsy syndrome	4.03e-06	4.79e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PTK2B—epilepsy syndrome	4.02e-06	4.77e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TSC1—epilepsy syndrome	4.02e-06	4.77e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—H2AFX—epilepsy syndrome	4.02e-06	4.77e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MEF2C—epilepsy syndrome	4.01e-06	4.76e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—SOCS3—epilepsy syndrome	4e-06	4.74e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CDC42—epilepsy syndrome	3.99e-06	4.73e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—AGT—epilepsy syndrome	3.96e-06	4.7e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CXCL12—epilepsy syndrome	3.96e-06	4.7e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—BDKRB2—epilepsy syndrome	3.96e-06	4.7e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—epilepsy syndrome	3.96e-06	4.7e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—POMC—epilepsy syndrome	3.95e-06	4.69e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—AVP—epilepsy syndrome	3.95e-06	4.68e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—PRKCB—epilepsy syndrome	3.94e-06	4.68e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—IL6ST—epilepsy syndrome	3.93e-06	4.66e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CCR2—epilepsy syndrome	3.91e-06	4.64e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NTRK2—epilepsy syndrome	3.91e-06	4.64e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—SST—epilepsy syndrome	3.91e-06	4.64e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CNR1—epilepsy syndrome	3.89e-06	4.61e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—JUNB—epilepsy syndrome	3.89e-06	4.61e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—DUSP6—epilepsy syndrome	3.88e-06	4.6e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—YWHAZ—epilepsy syndrome	3.88e-06	4.6e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PLCB1—epilepsy syndrome	3.87e-06	4.6e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—AVP—epilepsy syndrome	3.86e-06	4.58e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—NGF—epilepsy syndrome	3.84e-06	4.55e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PLAT—epilepsy syndrome	3.81e-06	4.53e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HTR7—epilepsy syndrome	3.79e-06	4.5e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—SRC—epilepsy syndrome	3.75e-06	4.45e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CCR5—epilepsy syndrome	3.73e-06	4.43e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—HES1—epilepsy syndrome	3.73e-06	4.43e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—KCNJ11—epilepsy syndrome	3.73e-06	4.42e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CHRM3—epilepsy syndrome	3.73e-06	4.42e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HBEGF—epilepsy syndrome	3.68e-06	4.37e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—BDKRB2—epilepsy syndrome	3.68e-06	4.37e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CXCL12—epilepsy syndrome	3.68e-06	4.37e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—POMC—epilepsy syndrome	3.67e-06	4.36e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—PRKCB—epilepsy syndrome	3.66e-06	4.35e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—VEGFA—epilepsy syndrome	3.65e-06	4.33e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—HTR2A—epilepsy syndrome	3.65e-06	4.33e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—HES1—epilepsy syndrome	3.65e-06	4.33e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—IL6ST—epilepsy syndrome	3.65e-06	4.33e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—FYN—epilepsy syndrome	3.63e-06	4.3e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—H2AFX—epilepsy syndrome	3.61e-06	4.29e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—AKT3—epilepsy syndrome	3.61e-06	4.29e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—JUNB—epilepsy syndrome	3.61e-06	4.29e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CNR1—epilepsy syndrome	3.61e-06	4.29e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MEF2C—epilepsy syndrome	3.61e-06	4.28e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PLCB1—epilepsy syndrome	3.6e-06	4.27e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—POMC—epilepsy syndrome	3.59e-06	4.26e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—HMOX1—epilepsy syndrome	3.58e-06	4.25e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—FYN—epilepsy syndrome	3.55e-06	4.21e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—H2AFX—epilepsy syndrome	3.54e-06	4.2e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—CAT—epilepsy syndrome	3.53e-06	4.19e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—ADAM10—epilepsy syndrome	3.53e-06	4.19e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MEF2C—epilepsy syndrome	3.53e-06	4.19e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—POMC—epilepsy syndrome	3.53e-06	4.19e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HTR7—epilepsy syndrome	3.52e-06	4.18e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—CCL2—epilepsy syndrome	3.51e-06	4.17e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—YWHAZ—epilepsy syndrome	3.49e-06	4.14e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—AGT—epilepsy syndrome	3.47e-06	4.12e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TSC2—epilepsy syndrome	3.47e-06	4.12e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—AGT—epilepsy syndrome	3.46e-06	4.11e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—NGF—epilepsy syndrome	3.45e-06	4.09e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—ABCB1—epilepsy syndrome	3.44e-06	4.08e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HBEGF—epilepsy syndrome	3.42e-06	4.06e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—YWHAZ—epilepsy syndrome	3.41e-06	4.05e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—epilepsy syndrome	3.4e-06	4.04e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—APOE—epilepsy syndrome	3.39e-06	4.03e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—NGF—epilepsy syndrome	3.37e-06	4e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—AKT3—epilepsy syndrome	3.36e-06	3.98e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CCR5—epilepsy syndrome	3.35e-06	3.98e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—S100B—epilepsy syndrome	3.34e-06	3.96e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—POMC—epilepsy syndrome	3.34e-06	3.96e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—KDR—epilepsy syndrome	3.33e-06	3.95e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—SOCS3—epilepsy syndrome	3.31e-06	3.92e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CDC42—epilepsy syndrome	3.3e-06	3.91e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—HTR2A—epilepsy syndrome	3.28e-06	3.9e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CCR5—epilepsy syndrome	3.28e-06	3.89e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—ADAM10—epilepsy syndrome	3.28e-06	3.89e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—CCL2—epilepsy syndrome	3.26e-06	3.87e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—ALB—epilepsy syndrome	3.22e-06	3.82e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—HTR2A—epilepsy syndrome	3.21e-06	3.81e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PRKCB—epilepsy syndrome	3.2e-06	3.8e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—GPX1—epilepsy syndrome	3.19e-06	3.79e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—AVP—epilepsy syndrome	3.19e-06	3.79e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IL6ST—epilepsy syndrome	3.19e-06	3.78e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TSC2—epilepsy syndrome	3.12e-06	3.7e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—AGT—epilepsy syndrome	3.11e-06	3.7e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—S100B—epilepsy syndrome	3.1e-06	3.68e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—SOCS3—epilepsy syndrome	3.07e-06	3.64e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CDC42—epilepsy syndrome	3.06e-06	3.64e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—APOE—epilepsy syndrome	3.05e-06	3.62e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TSC2—epilepsy syndrome	3.05e-06	3.62e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—AGT—epilepsy syndrome	3.05e-06	3.62e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ABCG2—epilepsy syndrome	3.04e-06	3.61e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HES1—epilepsy syndrome	3.02e-06	3.58e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—KDR—epilepsy syndrome	2.99e-06	3.55e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—APOE—epilepsy syndrome	2.99e-06	3.54e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—AVP—epilepsy syndrome	2.97e-06	3.52e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CYP2C19—epilepsy syndrome	2.96e-06	3.51e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CYP11A1—epilepsy syndrome	2.94e-06	3.49e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—FYN—epilepsy syndrome	2.94e-06	3.48e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—KDR—epilepsy syndrome	2.92e-06	3.47e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—H2AFX—epilepsy syndrome	2.92e-06	3.47e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	2.92e-06	3.47e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MEF2C—epilepsy syndrome	2.92e-06	3.46e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—POMC—epilepsy syndrome	2.92e-06	3.46e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PRKCB—epilepsy syndrome	2.88e-06	3.42e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IL6ST—epilepsy syndrome	2.87e-06	3.4e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CCL2—epilepsy syndrome	2.85e-06	3.39e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—YWHAZ—epilepsy syndrome	2.82e-06	3.35e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PRKCB—epilepsy syndrome	2.82e-06	3.34e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—PTGS2—epilepsy syndrome	2.81e-06	3.34e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HES1—epilepsy syndrome	2.8e-06	3.33e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IL6ST—epilepsy syndrome	2.8e-06	3.33e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—AGT—epilepsy syndrome	2.8e-06	3.32e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NGF—epilepsy syndrome	2.79e-06	3.31e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—APOE—epilepsy syndrome	2.74e-06	3.26e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—FYN—epilepsy syndrome	2.73e-06	3.24e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—H2AFX—epilepsy syndrome	2.72e-06	3.22e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CCR5—epilepsy syndrome	2.71e-06	3.22e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MEF2C—epilepsy syndrome	2.71e-06	3.22e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	2.66e-06	3.16e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HTR2A—epilepsy syndrome	2.66e-06	3.15e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CYP2D6—epilepsy syndrome	2.66e-06	3.15e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—YWHAZ—epilepsy syndrome	2.62e-06	3.11e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—POMC—epilepsy syndrome	2.62e-06	3.11e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NGF—epilepsy syndrome	2.59e-06	3.08e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—FGF2—epilepsy syndrome	2.58e-06	3.06e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CCL2—epilepsy syndrome	2.57e-06	3.04e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—POMC—epilepsy syndrome	2.56e-06	3.04e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ADRA2A—epilepsy syndrome	2.53e-06	3e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TSC2—epilepsy syndrome	2.52e-06	2.99e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CCR5—epilepsy syndrome	2.52e-06	2.99e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—AGT—epilepsy syndrome	2.52e-06	2.99e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—BCHE—epilepsy syndrome	2.52e-06	2.99e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CCL2—epilepsy syndrome	2.51e-06	2.98e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—APOE—epilepsy syndrome	2.47e-06	2.93e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HTR2A—epilepsy syndrome	2.47e-06	2.93e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—KDR—epilepsy syndrome	2.42e-06	2.87e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—SLC2A1—epilepsy syndrome	2.4e-06	2.85e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—RELA—epilepsy syndrome	2.39e-06	2.84e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PLCB1—epilepsy syndrome	2.38e-06	2.82e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—TH—epilepsy syndrome	2.37e-06	2.81e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—POMC—epilepsy syndrome	2.36e-06	2.8e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MTOR—epilepsy syndrome	2.35e-06	2.79e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TSC2—epilepsy syndrome	2.34e-06	2.78e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—AGT—epilepsy syndrome	2.34e-06	2.78e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—AKT1—epilepsy syndrome	2.33e-06	2.77e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	2.33e-06	2.77e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PRKCB—epilepsy syndrome	2.33e-06	2.76e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IL6ST—epilepsy syndrome	2.32e-06	2.75e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—FGF2—epilepsy syndrome	2.32e-06	2.75e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—APOE—epilepsy syndrome	2.29e-06	2.72e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—FGF2—epilepsy syndrome	2.27e-06	2.69e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—KDR—epilepsy syndrome	2.25e-06	2.67e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—AKT1—epilepsy syndrome	2.18e-06	2.59e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PRKCB—epilepsy syndrome	2.16e-06	2.57e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CASP3—epilepsy syndrome	2.16e-06	2.56e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IL6ST—epilepsy syndrome	2.15e-06	2.56e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—RELA—epilepsy syndrome	2.15e-06	2.55e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—ALB—epilepsy syndrome	2.15e-06	2.55e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—POMC—epilepsy syndrome	2.12e-06	2.52e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MTOR—epilepsy syndrome	2.11e-06	2.5e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—RELA—epilepsy syndrome	2.11e-06	2.5e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—JUN—epilepsy syndrome	2.1e-06	2.49e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CCL2—epilepsy syndrome	2.08e-06	2.46e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MTOR—epilepsy syndrome	2.06e-06	2.45e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MMP9—epilepsy syndrome	2.04e-06	2.42e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—AKT1—epilepsy syndrome	1.98e-06	2.35e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—HMOX1—epilepsy syndrome	1.98e-06	2.34e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—POMC—epilepsy syndrome	1.97e-06	2.34e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—AKT1—epilepsy syndrome	1.96e-06	2.32e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CAT—epilepsy syndrome	1.95e-06	2.31e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CASP3—epilepsy syndrome	1.94e-06	2.3e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CCL2—epilepsy syndrome	1.93e-06	2.29e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—AKT1—epilepsy syndrome	1.92e-06	2.27e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CASP3—epilepsy syndrome	1.9e-06	2.25e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ABCB1—epilepsy syndrome	1.9e-06	2.25e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—JUN—epilepsy syndrome	1.89e-06	2.24e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—SRC—epilepsy syndrome	1.88e-06	2.23e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—PTGS2—epilepsy syndrome	1.88e-06	2.23e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—FGF2—epilepsy syndrome	1.88e-06	2.23e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—JUN—epilepsy syndrome	1.84e-06	2.19e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MMP9—epilepsy syndrome	1.83e-06	2.18e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—VEGFA—epilepsy syndrome	1.83e-06	2.17e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MMP9—epilepsy syndrome	1.79e-06	2.13e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—AKT1—epilepsy syndrome	1.78e-06	2.11e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GPX1—epilepsy syndrome	1.76e-06	2.09e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—FGF2—epilepsy syndrome	1.74e-06	2.07e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—RELA—epilepsy syndrome	1.74e-06	2.07e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—AKT1—epilepsy syndrome	1.74e-06	2.07e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MTOR—epilepsy syndrome	1.71e-06	2.03e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—SRC—epilepsy syndrome	1.69e-06	2.01e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—SRC—epilepsy syndrome	1.65e-06	1.96e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—VEGFA—epilepsy syndrome	1.65e-06	1.95e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—RELA—epilepsy syndrome	1.62e-06	1.92e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—VEGFA—epilepsy syndrome	1.61e-06	1.91e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MTOR—epilepsy syndrome	1.59e-06	1.88e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—AKT1—epilepsy syndrome	1.59e-06	1.88e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CASP3—epilepsy syndrome	1.57e-06	1.86e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—AGT—epilepsy syndrome	1.55e-06	1.83e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—JUN—epilepsy syndrome	1.53e-06	1.81e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—APOE—epilepsy syndrome	1.51e-06	1.8e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MMP9—epilepsy syndrome	1.48e-06	1.76e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—AKT1—epilepsy syndrome	1.47e-06	1.75e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CASP3—epilepsy syndrome	1.46e-06	1.73e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—AKT1—epilepsy syndrome	1.44e-06	1.71e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—JUN—epilepsy syndrome	1.42e-06	1.68e-05	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—AKT1—epilepsy syndrome	1.41e-06	1.68e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MMP9—epilepsy syndrome	1.38e-06	1.64e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—SRC—epilepsy syndrome	1.37e-06	1.62e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—AKT1—epilepsy syndrome	1.34e-06	1.59e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—VEGFA—epilepsy syndrome	1.33e-06	1.58e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—POMC—epilepsy syndrome	1.3e-06	1.54e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—SRC—epilepsy syndrome	1.27e-06	1.51e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—VEGFA—epilepsy syndrome	1.24e-06	1.47e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ALB—epilepsy syndrome	1.19e-06	1.41e-05	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—AKT1—epilepsy syndrome	1.17e-06	1.39e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—AKT1—epilepsy syndrome	1.05e-06	1.25e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—PTGS2—epilepsy syndrome	1.04e-06	1.23e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—AKT1—epilepsy syndrome	1.03e-06	1.22e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—AKT1—epilepsy syndrome	9.45e-07	1.12e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—AKT1—epilepsy syndrome	8.5e-07	1.01e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—AKT1—epilepsy syndrome	7.9e-07	9.38e-06	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—AKT1—epilepsy syndrome	5.22e-07	6.19e-06	CbGpPWpGaD
